11 results
8-K
EX-99.1
ICU
SeaStar Medical Holding Corp
14 May 24
SeaStar Medical Reports First Quarter 2024 Financial Results and Provides a Business Update
4:05pm
with broad claims covering the SCD technology.
First Quarter Financial Results
Research and development (R&D) expenses for the first quarters of 2024
8-K
EX-99.1
ICU
SeaStar Medical Holding Corp
17 Apr 24
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update
4:01pm
and development (R&D) expenses for 2023 were $6.0 million, compared with $2.5 million for 2022, with the increase primarily driven by higher clinical trial
424B3
ICU
SeaStar Medical Holding Corp
5 Mar 24
Prospectus supplement
4:59pm
and execution of a pivotal study.
Third Quarter Financial Results
Research and development (R&D) expenses for the third quarter of 2023 were $1.1 … .
Nine Month Financial Results
R&D expenses for the first nine months of 2023 were $4.9 million, compared with $1.7 million for the first nine months
8-K
EX-99.1
ICU
SeaStar Medical Holding Corp
21 Nov 23
SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business Update
6:04pm
Quarter Financial Results
Research and development (R&D) expenses for the third quarter of 2023 were $1.1 million, compared with $0.7 million … , compared with a net loss of $1.9 million, or $0.26 per share, for the three months ended September 30, 2022.
Nine Month Financial Results
R&D expenses
8-K
EX-99.1
eb6eq2zw
14 Aug 23
SeaStar Medical Reports Second Quarter 2023 Financial Results and Provides a Business Update
6:46pm
424B3
3q0tlgfgj mjv
23 May 23
Prospectus supplement
5:29pm
424B3
kio7s8zc0muwevfy04
23 May 23
Prospectus supplement
5:24pm
424B3
s49n5sxaf1 blc
23 May 23
Prospectus supplement
5:20pm
8-K
EX-99.1
cqy91
16 May 23
SeaStar Medical Reports First Quarter 2023 Financial Results and Provides a Business Update
4:06pm
8-K
EX-99.1
bojzx7f zo8ypzgpnyf
30 Mar 23
SeaStar Medical Reports 2022 Financial Results and Provides a Business Update
9:58pm
- Prev
- 1
- Next